10-Q: Retractable Technologies Reports Q3 Profit Amid Tariff Headwinds

Retractable Technologies, Inc. reported a net profit of $0.37 million for Q3 2025, a significant improvement from a loss in the prior year, despite ongoing tariff impacts and strategic shifts to domestic manufacturing.

Summary

• Net sales for the three months ended September 30, 2025, were $10.09 million, a decrease from $10.35 million in the same period of 2024.
• Net sales for the nine months ended September 30, 2025, increased to $28.83 million from $23.98 million in the prior year period.
• The company achieved a net income of $0.37 million ($0.01 EPS) for Q3 2025, a turnaround from a net loss of $1.92 million ($0.07 loss per share) in Q3 2024.
• For the nine months ended September 30, 2025, the net loss was reduced to $10.22 million ($0.35 loss per share) from $15.66 million ($0.53 loss per share) in the prior year period.
• Gross profit significantly improved in Q3 2025 to $1.69 million from a loss of $14,810 in Q3 2024, driven by lower unit sales and a favorable product mix.
• Operating loss improved to $3.65 million in Q3 2025 from $5.14 million in Q3 2024.
• Tariffs on Chinese imports continue to materially impact costs, with $172,000 spent in Q3 2025 and $2.3 million in the first nine months of 2025.
• The company is shifting manufacturing of 1mL, 3mL, and EasyPoint needles to its domestic facility and expects to produce 0.5mL syringes domestically by H1 2026 to mitigate tariff effects.
• Cash and cash equivalents decreased to $3.44 million as of September 30, 2025, from $4.24 million at December 31, 2024.
• Investments in debt and equity securities decreased to $30.50 million from $40.33 million over the same period, with a $3.22 million unrealized loss for the nine months ended September 30, 2025.
• A $1.9 million litigation settlement payment was received in May 2025.

Sentiment

Score: 6

Explanation: The company showed a return to profitability in Q3 and significantly reduced its year-to-date net loss, indicating operational improvements. However, ongoing material impacts from tariffs, significant inventory write-downs, and an expected material decline in long-term liquidity present notable challenges. The strategic shift to domestic manufacturing is a positive long-term move but carries near-term cost increases.

Positives

• Achieved a net income of $371,047 in Q3 2025, a significant improvement from a net loss of $1,921,989 in Q3 2024.
• Gross profit for Q3 2025 was $1,685,904, a substantial turnaround from a gross loss of $14,810 in Q3 2024.
• Operating loss decreased to $3,654,042 in Q3 2025 from $5,135,744 in Q3 2024.
• Net loss for the nine months ended September 30, 2025, significantly reduced to $10,217,140 from $15,657,246 in the prior year period.
• Received a $1.9 million settlement payment in May 2025 from litigation with former legal counsel.
• Net cash used in operating activities for the nine months ended September 30, 2025, decreased to $6,467,836 from $10,452,299 in the prior year, indicating improved operational cash efficiency.
• Net cash from investing activities increased to $6,099,634 for the nine months ended September 30, 2025, primarily due to $7 million in proceeds from the sale of debt and equity securities.
• Domestic revenues increased 18.0% for the nine months ended September 30, 2025, compared to the same period in 2024.
• International revenues increased 38.1% for the nine months ended September 30, 2025, compared to the same period in 2024.

Negatives

• Net sales for Q3 2025 decreased by 2.5% to $10,085,723 compared to $10,346,857 in Q3 2024.
• Unrealized loss on debt and equity securities was $3,217,058 for the nine months ended September 30, 2025, a significant negative swing from a $1,402,660 gain in the prior year.
• Cash and cash equivalents decreased by $790,850 for the nine months ended September 30, 2025, to $3,444,538.
• Total assets decreased to $146,434,200 as of September 30, 2025, from $160,724,202 at December 31, 2024.
• Inventory write-downs of approximately $1.2 million were recorded for the nine months ended September 30, 2025, primarily due to products nearing expiration dates.
• Tariff expenses totaled approximately $2.3 million for the first nine months of 2025, materially impacting costs.
• Increased domestic manufacturing efforts are expected to incur higher manufacturing costs in the near term and raise payroll costs by approximately $825,000 on an annualized basis.
• Long-term liquidity is expected to decline materially over the next 1-3 years.
• Customer demand was diminished due to remaining syringe inventory held by domestic customers from prior vaccination efforts.

Risks

• Ongoing tariffs on products imported from China, with rates as high as 130% on syringes and needles, are expected to have a continuing material impact on results of operations and financial position.
• Reliance on Chinese manufacturers for 61.7% of products in the first nine months of 2025 poses a supply disruption risk if unable to purchase from them or produce domestically.
• Uncertainty regarding future tariff rates and affected products due to evolving foreign trade policy and ongoing trade negotiations with China and other nations.
• Increased domestic production to mitigate tariffs will lead to higher manufacturing workforce costs and potentially higher unit costs in the near term.
• Inability to recover increased costs (raw materials, transportation, tariffs, workforce) through product price increases.
• Material changes in demand for products, particularly those related to vaccinations, due to public sentiment and acceptance of vaccine efficacy.
• Maintaining liquidity given the expected material decline in long-term liquidity over the next 1-3 years.
• Maintaining patent protection for proprietary technology.
• Ability to maintain favorable third-party manufacturing and supplier arrangements and relationships.
• Foreign trade risk beyond tariffs, including geopolitical factors.
• Ability to access the market effectively against larger market players.
• Production costs fluctuations due to raw materials, transportation, tariffs, workforce, and changing production volumes.

Future Outlook

The company expects tariffs to continue having a material impact on its results and financial position. Efforts to lessen this impact include strategically ordering from Chinese suppliers and shifting more manufacturing to its domestic facility, which will increase manufacturing workforce costs by approximately $825,000 annually. Commercial quantities of domestically produced 0.5mL syringes are anticipated in the first half of 2026. Seasonal trends for syringe sales may be returning to pre-pandemic patterns, with potential increased demand for EasyPoint products during flu season, especially in retail pharmacy. Long-term liquidity is expected to decline materially over the next 1-3 years, though the company believes it has adequate means to meet short-term needs.

Management Comments

• "Tariffs are expected to have a continuing material impact to our results of operations and financial position."
• "We are working to lessen the financial impact of the tariffs through strategic ordering of products from our Chinese suppliers and shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint needles to our domestic manufacturing facility."
• "We currently anticipate that commercial quantities [of domestically produced 0.5mL syringes] will become available, as market demand necessitates, in the first half of 2026."
• "Manufacturing workforce increases instituted in 2025 will raise payroll costs by approximately $825 thousand on an annualized basis."
• "We believe domestic customers retained products provided for vaccination purposes in inventory. Customers have reported that demand was diminished due to their remaining syringe inventory."
• "Seasonal trends for syringe sales may now be following pre-pandemic patterns. Additionally, there may be more demand for EasyPoint products during the flu season, particularly in the retail pharmacy market."
• "We believe we will have adequate means to meet our short-term needs to fund operations for at least 12 months from the date of issuance of the financial statements."
• "For the next 1-3 years, we believe our liquidity will decline materially, but we expect that we may be able to satisfy our long-term cash requirements using a combination of cash and liquidation of our equity investments."

Industry Context

The medical device industry, particularly for syringes and needles, is experiencing shifts due to global trade policies, such as U.S. tariffs on Chinese imports, prompting companies like Retractable Technologies to re-evaluate supply chains and increase domestic manufacturing. The post-COVID-19 pandemic environment has also impacted demand patterns, with a return to pre-pandemic seasonality for syringe sales and a potential increase in demand for specific products like EasyPoint during flu seasons. The market is also influenced by public sentiment regarding vaccinations and the presence of larger market players.

Comparison to Industry Standards

• NA

Legal Proceedings

• Received a $1.9 million settlement payment in May 2025 related to the resolution of litigation with former legal counsel.

Related Party Transactions

• Thomas J. Shaw, President, Chairman, and CEO, receives a 5% royalty fee on gross sales of products utilizing his patented technology and 50% of royalties paid by certain sublicensees.
• Thomas J. Shaw adopted a Rule 10b5-1 plan on August 22, 2024, to purchase up to $800,000 of common stock through November 19, 2025.

Stakeholder Impact

• Shareholders: Experienced a net profit in Q3 2025 and reduced year-to-date net loss, but also a decrease in total assets and stockholders' equity. Preferred shareholders continue to receive dividends, with efforts ongoing to contact former shareholders owed $1.4 million.
• Employees: Workforce levels increased due to higher domestic manufacturing, despite reductions in non-manufacturing functions, leading to higher payroll costs.
• Customers: Domestic customers' demand was diminished due to existing syringe inventory from prior vaccination efforts. International customers received EasyPoint needles at a discount, impacting average selling prices.
• Suppliers: Reduced reliance on Chinese manufacturers (61.7% of products in YTD 2025 vs. 90% in YTD 2024) due to tariffs, impacting supplier relationships and potentially shifting business to domestic suppliers.
• Creditors: Long-term debt repayments continue, and the company believes it has adequate means to meet short-term obligations, though long-term liquidity is expected to decline materially.

Next Steps

• Continue efforts to lessen the financial impact of tariffs through strategic ordering and shifting manufacturing to domestic facilities.
• Increase domestic production of 1mL, 3mL, and EasyPoint needles.
• Complete adaptations to existing equipment to produce 0.5mL syringes domestically, with commercial quantities expected in H1 2026.
• Manage increased manufacturing workforce costs associated with higher domestic production.
• Continue efforts to establish contact with approximately 90 former shareholders entitled to $1.4 million in preferred stock dividends.

Key Dates

Recommendation

The company demonstrated a significant turnaround to profitability in Q3 2025 and a reduced net loss year-to-date, indicating some operational improvements. Strategic initiatives to increase domestic manufacturing are a necessary response to tariffs and could improve long-term resilience. However, the material impact of tariffs, substantial inventory write-downs, and an expected material decline in long-term liquidity present considerable headwinds. The volatility in investment gains/losses also adds uncertainty. Given the mixed financial performance, ongoing strategic adjustments, and significant risks, a 'hold' recommendation is appropriate. Investors should monitor the effectiveness of domestic manufacturing shifts, the impact of tariffs, and the company's ability to manage its liquidity and inventory.

Keywords

safety syringes, medical devices, tariffs, domestic manufacturing, SEC filing, financial results, Q3 2025, Retractable Technologies, RVP, healthcare, syringes, needles, EasyPoint, VanishPoint, BARDA, COVID-19, supply chain, profitability, liquidity